We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
$1-million price tag set for Glybera gene therapy.
- Authors
Morrison, Chris
- Abstract
The article reports that the first gene therapy approved in the U.S. is set to go on sale at about $1 million per treatment in Germany. The price came out in November 2014, when Amsterdam-based Uniqure BV and its Parma, Italy-based marketing partner Chiesi Farmaceutici SpA filed a pricing dossier with German authorities to launch Glybera. The focus on gene therapies sharpened further when Cambridge, Massachusetts-based Bluebird Bio presented clinical data from four beta-thalassemia patients.
- Subjects
UNITED States; GENE therapy; UNIQURE BV; CHIESI Farmaceutici SpA; BLUEBIRD Bio Inc.
- Publication
Nature Biotechnology, 2015, Vol 33, Issue 3, p217
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0315-217